• Safety & Recalls
  • Regulatory Updates
  • Drug Coverage
  • COPD
  • Cardiovascular
  • Obstetrics-Gynecology & Women's Health
  • Ophthalmology
  • Clinical Pharmacology
  • Pediatrics
  • Urology
  • Pharmacy
  • Idiopathic Pulmonary Fibrosis
  • Diabetes and Endocrinology
  • Allergy, Immunology, and ENT
  • Musculoskeletal/Rheumatology
  • Respiratory
  • Psychiatry and Behavioral Health
  • Dermatology
  • Oncology

FDA actions in brief, February 2010 (Ampyra, Victoza, Actemra, Tropazone, Morphine sulfate oral solution, Fluzone High-Dose)


Recent FDA approvals (through February 2010) related to Ampyra, Victoza, Actemra, Tropazone, Morphine sulfate oral solution, Fluzone High-Dose

Dalfampridine extended release tablets (Ampyra, Acorda Therapeutics) was approved to improve walking in patients with multiple sclerosis.

Liraglutide once-daily injection (Victoza, Novo Nordisk) was approved for treatment of type 2 diabetes in some adults.

Tocilizumab (Actemra, Roche Holding) was approved for moderate to severe rheumatoid arthritis in adults who have not achieved an adequate response with one or more tumor necrosis factor antagonist therapies.

Morphine sulfate oral solution (Roxane Laboratories) in the 100-mg-per-5-mL and 20-mg-per-mL strengths was approved for the relief of moderate to severe, acute and chronic pain in opioid-tolerant patients.

Inactivated influenza virus vaccine (Fluzone High-Dose, Sanofi Pasteur) was approved for active immunization of people 65 and older.

© 2024 MJH Life Sciences

All rights reserved.